Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Future directions of CAM research in pediatric oncology.
Post-White J, Hawks R, O'Mara A, Ott MJ. Post-White J, et al. Among authors: hawks r. J Pediatr Oncol Nurs. 2006 Sep-Oct;23(5):265-8. doi: 10.1177/1043454206291361. J Pediatr Oncol Nurs. 2006. PMID: 16902081 Review.
Evidence for symptom management in the child with cancer.
Ladas EJ, Post-White J, Hawks R, Taromina K. Ladas EJ, et al. Among authors: hawks r. J Pediatr Hematol Oncol. 2006 Sep;28(9):601-15. doi: 10.1097/01.mph.0000212989.26317.52. J Pediatr Hematol Oncol. 2006. PMID: 17006267 Review.
Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME. Gaynon PS, et al. Among authors: hawks r. J Clin Oncol. 2006 Jul 1;24(19):3150-6. doi: 10.1200/JCO.2005.04.5856. Epub 2006 May 22. J Clin Oncol. 2006. PMID: 16717292 Clinical Trial.
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS. Satwani P, et al. Among authors: hawks r. Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9. Biol Blood Marrow Transplant. 2012. PMID: 22079471 Free article. Clinical Trial.
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.
Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E, Garvin J, Bradley MB, Bhatia M, Satwani P, George D, Del Toro G, Hawks R, Wolownik K, Foley S, Cheung YK, Schwartz J, van de Ven C, Baxter-Lowe LA, Cairo MS. Waxman IM, et al. Among authors: hawks r. Pediatr Transplant. 2009 Jun;13(4):464-74. doi: 10.1111/j.1399-3046.2008.01000.x. Epub 2008 Sep 10. Pediatr Transplant. 2009. PMID: 18785912
57 results